Heidi powers the largest AI scribe procurement in NHS history. 70,000 Clinicians. 15 NHS Trusts. 1,200+ GP Practices. Learn more.
Dictate anywhere on your screen, capture telehealth audio straight from the call,
and skip the second login.
Warning: Clinical review pending: not for clinical use
Before you score. A self-report screener, not a diagnostic instrument. Scores over the past 2 weeks; interpret alongside clinical interview.
Feeling nervous, anxious, or on edge
Not being able to stop or control worrying
Worrying too much about different things
Trouble relaxing
Being so restless that it's hard to sit still
Becoming easily annoyed or irritable
Feeling afraid, as if something awful might happen
For clinical decision support only. Always integrate with full clinical assessment, local guidelines, and patient preferences.
GAD-7 is a validated, self-administered 7-item questionnaire used to screen for and measure the severity of Generalized Anxiety Disorder (GAD). It takes around a couple of minutes to complete. Calculate GAD-7 scores below:
Every summary carries citations with verbatim excerpts from the source, so you can open it, read it in context and confirm it says what the answer claims. What surfaces are decided by clinical quality, the governed alternative to pasting a clinical question into a general AI chatbot and hoping the answer holds.
Heidi Evidence draws on sources clinicians already trust, from Elsevier and DynaMed to MIMS Australia, and your organization can layer in its own regional pathways, policies, and formularies.
Heidi is the first in its field to hold ISO 42001 certification for AI management. Since Evidence is designed as a reference tool, the clinical call (and the responsibility for it) stays with you.
Evidence draws on the patient visit and its context, so the specifics travel with the question instead of being left behind. When a calculation is involved, the logic sits alongside the result, so you can see how it was reached and confirm it yourself rather than trust a black box.
Making that connection between the patient and the GP, like a puzzle fitting together.
Deborah Hawthorne
Clinicians at Connect2Care
Medical knowledge only. Not for autonomous decision making. Check sources and use your clinical judgement.
Before initiating any treatment, exclude medical causes of anxiety (e.g., thyroid dysfunction, arrhythmia, anaemia) through targeted history and investigation. The GAD-7 score then sets the entry point in a stepped-care pathway: 5-9 (mild) starts with low-intensity psychological interventions such as guided self-help or psychoeducational groups; 10-14 (moderate) calls for high-intensity CBT or pharmacotherapy by patient preference; and 15 or above signals active treatment with consideration of specialist referral, depending on functional impairment, safety concerns, and treatment response.
SSRIs and SNRIs are first-line pharmacotherapy across major guidelines, with sertraline and escitalopram the usual starting agents. To reduce initial anxiety exacerbation, begin at half the standard dose for the first 1 to 2 weeks before titrating to a therapeutic dose. Allow 4 to 6 weeks at a therapeutic dose before assessing pharmacological response; a full 12-week trial may be needed for maximal effect. CBT carries the strongest psychotherapy evidence and performs comparably to medication for generalized anxiety disorder.
Continue antidepressants for at least 6 to 12 months after response, because earlier discontinuation drives relapse in a substantial share of patients. Benzodiazepines remain off the first line and belong to short-term or bridging use only (maximum 2 to 4 weeks), given dependence and rebound risk.